🧬 一种同时靶向 DLL4 + VEGF-A 的双特异性药物显然能够改善缓解率和 PFS——但毒性与获益之间的权衡很重要。
@OncoAlert @myESMO
在 #ESMO26 上，一项随机 2/3 期试验在既往接受过治疗的晚期胆道癌患者中，比较了 tovecimig + 紫杉醇与紫杉醇单药。
📊 n=168
➡️ ORR：17.1% vs 5.3%
p=0.031
➡️ 中位 PFS：4.7 vs 2.6 个月
HR 0.44, p<0.0001
➡️ OS：HR 1.05
解读受到 54% 交叉使用的限制
但安全性信号值得关注：
⚠️ ≥3 级高血压：44%
⚠️ 因 TEAEs 停药：40% vs 15%
🎯 为何重要：疗效信号是真实存在的，尤其是 PFS；但在经过大量既往治疗的人群中，临床价值将取决于我们能否识别出获益足以证明新增毒性合理性的患者。
对我而言，下一个问题是，Dll4/VEGF 生物学能否成为真正的选择策略，而非另一种被广泛应用的抗血管生成治疗方式。
来自 @DrElkhoueiry、@JavleMilind 及合作者的重要数据。
特此提醒 @CathyEngMD @BenWestphalen @graokane @NiuSanford @GillSharlene @pashtoonkasi @DrVilmaPBarcia @GIMedOnc @DaisukeKotani @KoheiShitara
#OncoAlert #ESMO26 #BiliaryTractCancer #GIOncology #Bispecifics #PrecisionOncology
94 浏览 · 3 赞 · 1 转发 · 0 回复
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.orgOncoAlert 4Sight Abstracts to be Presented at #ESMO26 A Randomized Trial of Paclitaxel ± Tovecimig in Previously Treated Patients With Advanced Biliary Tract Cancer @DrElkhoueiry @JavleMilind 🔬 Randomized phase 2/3 (n=168, 2:1): tovecimig (DLL4 × VEGF-A bispecific) + paclitaxel vs paclitaxel in previously treated advanced BTC. Primary endpoint: BICR ORR. ➡️ ORR 17.1% vs 5.3% (p=0.031); median PFS 4.7 vs 2.6 mo, HR 0.44 (p<0.0001) ➡️ OS HR 1.05 (p=0.78); 54% crossed over to tovecimig + paclitaxel ➡️ Related grade ≥3 hypertension 44%; TEAEs leading to discontinuation 40% vs 15% ✅ Significant ORR and PFS advantage; OS analysis confounded by high crossover, precluding a meaningful comparison. 🎙️ Nilofer Azad 👥 Zishuo Hu · Ilyas Sahin · Renuka Iyer · Olivia Aranha · Howard Hochster · Priyadarshini Pathak · Scott Paulson · Aparna Kalyan · Chih-Yi Liao · Nguyen Tran · Robin Kelley · Gregory Heestand · David Cosgrove · Anthony El-Khoueiry · Mitesh Borad · Nashat Gabrail · Umair Majeed · Lingling Du · Suneel Kamath · Nathan Shumway · Rachna Shroff · Lipika Goyal · Minori Rosales · Milind Javle (4Sight Made from Abstracts publicly available at the ESMO website) @CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, , @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara,在 X 查看被引用的帖子
来源：Dra. María Natalia Gandur Quiroga · x.com